# Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

> **NCT00183820** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 30 (actual)

## Conditions studied

- Testicular Cancer
- Germ Cell Neoplasm

## Interventions

- **DRUG:** paclitaxel, gemcitabine, and oxaliplatin

## Key facts

- **NCT ID:** NCT00183820
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2015-12
- **Final completion:** 2016-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00183820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00183820, "Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00183820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*